REED JOHN C

Insider Reports History

Location
New Brunswick, NJ
Signature
/s/ Laura H. McFalls, as attorney-in-fact for John C. Reed
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by REED JOHN C:

Company Role Class Num Shares Value Price $ Report Date Ownership
JOHNSON & JOHNSON EVP, Innovative Medicine, R&D Employee Stock Options (Right to Buy) 43,442 $6,860,360 $157.92 17 Oct 2025 Direct
JOHNSON & JOHNSON EVP, Innovative Medicine, R&D Common Stock 10,658 $2,053,873 $192.71 17 Oct 2025 Direct
JOHNSON & JOHNSON EVP, Innovative Medicine, R&D Restricted Share Units 25,255 $864,915 $156.15 01 May 2025 Direct

Insider Reports Filed by REED JOHN C

Symbol Company Period Transactions Value $ Form Type Role Filing Time
JNJ JOHNSON & JOHNSON 17 Oct 2025 3 -$4,185,793 4 EVP, Innovative Medicine, R&D 20 Oct 2025, 19:13
JNJ JOHNSON & JOHNSON 17 Jul 2025 1 -$3,129,830 4 EVP, Innovative Medicine, R&D 18 Jul 2025, 16:12
JNJ JOHNSON & JOHNSON 01 May 2025 3 -$1,719,723 4 EVP, Innovative Medicine, R&D 05 May 2025, 17:10
JNJ JOHNSON & JOHNSON 15 Feb 2025 2 $0 4 EVP, Innovative Medicine, R&D 19 Feb 2025, 17:29
JNJ JOHNSON & JOHNSON 15 Feb 2025 3 -$60,118 4 EVP, Innovative Medicine, R&D 18 Feb 2025, 21:11
JNJ JOHNSON & JOHNSON 01 May 2024 3 -$1,588,177 4/A EVP, Innovative Medicine, R&D 31 Oct 2024, 17:57
JNJ JOHNSON & JOHNSON 15 Feb 2024 2 $0 4 EVP, Innovative Medicine, R&D 20 Feb 2024, 17:55
JNJ JOHNSON & JOHNSON 01 May 2023 1 $0 4 EVP, Pharmaceuticals R&D 02 May 2023, 17:21
JNJ JOHNSON & JOHNSON 03 Apr 2023 0 $0 3 EVP, Pharmaceuticals R&D 13 Apr 2023, 17:10